Clinical Trials
68 trialsA Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Guangdong Association of Clinical Trials
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
Sun Yat-sen University
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Eastern Cooperative Oncology Group
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Sichuan University
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
SWOG Cancer Research Network
SC9/ABX
Northwestern University
METAGIO
Bristol-Myers Squibb
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer
Indiana University
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NIRVANA-LUNG
UNICANCER
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
M.D. Anderson Cancer Center
GC/GEJC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
RAPID
Children's Hospital Los Angeles
ORATOR2
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
ILDR-03
Shantou University Medical College
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
g-RAMPP
Martini-Klinik am UKE GmbH
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
M.D. Anderson Cancer Center
ESO-Nanjing7
Jiangsu Cancer Institute & Hospital
MPM-PDT
Abramson Cancer Center at Penn Medicine
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
FORTITUDE-102
Amgen
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RETINO2011
Institut Curie
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shanghai Henlius Biotech
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
Bristol-Myers Squibb
OPTIMIZE-1
Alligator Bioscience AB
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
NEOLBC
Borstkanker Onderzoek Groep
SABR-COMET 10
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Drug-SNP
Medicine Invention Design, Inc
OMET
Groupe Oncologie Radiotherapie Tete et Cou
CORINTH
Cardiff University
Young Patients With Early Breast Cancer
Peking Union Medical College Hospital
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
M.D. Anderson Cancer Center
Drugs-SNPs
Medicine Invention Design, Inc
CHORUS
Memorial Sloan Kettering Cancer Center
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
TOG-SAFRADJU
Ankara University